Matches in Wikidata for { <http://www.wikidata.org/entity/Q91634065> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q91634065 description "article scientifique publié en 2020" @default.
- Q91634065 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q91634065 description "scientific article published on 01 March 2020" @default.
- Q91634065 description "wetenschappelijk artikel" @default.
- Q91634065 description "наукова стаття, опублікована 1 березня 2020" @default.
- Q91634065 name "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 name "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 type Item @default.
- Q91634065 label "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 label "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 prefLabel "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 prefLabel "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 P1433 Q91634065-94F2C41B-F837-4590-8AE1-5C9CEB29E92B @default.
- Q91634065 P1476 Q91634065-E13BCC36-02B1-458F-86A1-6A33A1FAF444 @default.
- Q91634065 P2093 Q91634065-03DCAC9A-2A51-4A51-9E18-D1C91DE2AE95 @default.
- Q91634065 P2093 Q91634065-124FBBB7-268E-486F-AEAB-8CC11D3E5F62 @default.
- Q91634065 P2093 Q91634065-1C08727F-6A38-4C75-818C-6FEA58EAA4D2 @default.
- Q91634065 P2093 Q91634065-3A17D603-3575-4E07-A0ED-E04169244BAE @default.
- Q91634065 P2093 Q91634065-6F52E610-6F88-449A-96B8-FBCE4D6F8D58 @default.
- Q91634065 P2093 Q91634065-FC958211-7FF6-4C9A-893F-E6DA9C4051E9 @default.
- Q91634065 P304 Q91634065-43F4FD20-153A-46CB-A1E1-D48D9F993477 @default.
- Q91634065 P31 Q91634065-D1FDBDDB-234A-4383-B7A7-80FAA0C5DEC7 @default.
- Q91634065 P356 Q91634065-2D213A6D-A38F-4EFC-9DE2-1AE256518EA5 @default.
- Q91634065 P433 Q91634065-9DD96900-6CC5-424F-8F42-9D0376E4703A @default.
- Q91634065 P478 Q91634065-072D98CD-36F7-40D5-80FA-2A2C44D0AC11 @default.
- Q91634065 P577 Q91634065-2B51332D-6F48-4A94-B20C-89E25BD0AA40 @default.
- Q91634065 P698 Q91634065-B0B130B5-4F96-4121-ADCA-1D71DAC0B1BE @default.
- Q91634065 P921 Q91634065-7CB60B31-9BDF-4AB7-BA4A-B2546CE3A998 @default.
- Q91634065 P921 Q91634065-A0658939-5297-4E2E-AF3F-FCD935FB859C @default.
- Q91634065 P356 DKZ488 @default.
- Q91634065 P698 31794023 @default.
- Q91634065 P1433 Q6294770 @default.
- Q91634065 P1476 "Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections" @default.
- Q91634065 P2093 "Alina Karoline Nussbaumer-Pröll" @default.
- Q91634065 P2093 "Birgit Reiter" @default.
- Q91634065 P2093 "Christoph Dorn" @default.
- Q91634065 P2093 "Markus Zeitlinger" @default.
- Q91634065 P2093 "Sabine Eberl" @default.
- Q91634065 P2093 "Thomas Stimpfl" @default.
- Q91634065 P304 "593-599" @default.
- Q91634065 P31 Q13442814 @default.
- Q91634065 P356 "10.1093/JAC/DKZ488" @default.
- Q91634065 P433 "3" @default.
- Q91634065 P478 "75" @default.
- Q91634065 P577 "2020-03-01T00:00:00Z" @default.
- Q91634065 P698 "31794023" @default.
- Q91634065 P921 Q221668 @default.
- Q91634065 P921 Q40936 @default.